AMAR REMEDIES | RELAXO FOOTWEARS | AMAR REMEDIES/ RELAXO FOOTWEARS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -0.5 | 100.1 | - | View Chart |
P/BV | x | 0.1 | 18.6 | 0.3% | View Chart |
Dividend Yield | % | 0.0 | 0.2 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AMAR REMEDIES Jun-12 |
RELAXO FOOTWEARS Mar-19 |
AMAR REMEDIES/ RELAXO FOOTWEARS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 164 | 874 | 18.8% | |
Low | Rs | 86 | 635 | 13.5% | |
Sales per share (Unadj.) | Rs | 261.6 | 184.8 | 141.6% | |
Earnings per share (Unadj.) | Rs | 17.4 | 14.1 | 123.0% | |
Cash flow per share (Unadj.) | Rs | 22.3 | 19.2 | 116.2% | |
Dividends per share (Unadj.) | Rs | 0 | 1.80 | 0.0% | |
Dividend yield (eoy) | % | 0 | 0.2 | 0.0% | |
Book value per share (Unadj.) | Rs | 100.7 | 89.1 | 113.1% | |
Shares outstanding (eoy) | m | 26.16 | 124.05 | 21.1% | |
Bonus/Rights/Conversions | - | ESOP | - | ||
Price / Sales ratio | x | 0.5 | 4.1 | 11.7% | |
Avg P/E ratio | x | 7.2 | 53.3 | 13.5% | |
P/CF ratio (eoy) | x | 5.6 | 39.4 | 14.3% | |
Price / Book Value ratio | x | 1.2 | 8.5 | 14.7% | |
Dividend payout | % | 0 | 12.7 | 0.0% | |
Avg Mkt Cap | Rs m | 3,270 | 93,596 | 3.5% | |
No. of employees | `000 | NA | 6.3 | 0.0% | |
Total wages/salary | Rs m | 163 | 2,587 | 6.3% | |
Avg. sales/employee | Rs Th | NM | 3,665.0 | - | |
Avg. wages/employee | Rs Th | NM | 413.6 | - | |
Avg. net profit/employee | Rs Th | NM | 280.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 6,844 | 22,921 | 29.9% | |
Other income | Rs m | 21 | 130 | 16.2% | |
Total revenues | Rs m | 6,865 | 23,051 | 29.8% | |
Gross profit | Rs m | 1,131 | 3,243 | 34.9% | |
Depreciation | Rs m | 128 | 624 | 20.5% | |
Interest | Rs m | 398 | 69 | 576.8% | |
Profit before tax | Rs m | 626 | 2,680 | 23.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -50 | 0 | - | |
Tax | Rs m | 121 | 925 | 13.1% | |
Profit after tax | Rs m | 455 | 1,754 | 25.9% | |
Gross profit margin | % | 16.5 | 14.1 | 116.8% | |
Effective tax rate | % | 19.3 | 34.5 | 56.0% | |
Net profit margin | % | 6.6 | 7.7 | 86.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 4,904 | 7,201 | 68.1% | |
Current liabilities | Rs m | 3,581 | 4,560 | 78.5% | |
Net working cap to sales | % | 19.3 | 11.5 | 167.8% | |
Current ratio | x | 1.4 | 1.6 | 86.7% | |
Inventory Days | Days | 124 | 64 | 194.3% | |
Debtors Days | Days | 100 | 31 | 319.9% | |
Net fixed assets | Rs m | 1,689 | 8,595 | 19.7% | |
Share capital | Rs m | 262 | 124 | 211.3% | |
"Free" reserves | Rs m | 2,358 | 10,927 | 21.6% | |
Net worth | Rs m | 2,635 | 11,051 | 23.8% | |
Long term debt | Rs m | 507 | 0 | - | |
Total assets | Rs m | 6,862 | 16,046 | 42.8% | |
Interest coverage | x | 2.6 | 39.8 | 6.5% | |
Debt to equity ratio | x | 0.2 | 0 | - | |
Sales to assets ratio | x | 1.0 | 1.4 | 69.8% | |
Return on assets | % | 12.4 | 11.4 | 109.4% | |
Return on equity | % | 17.3 | 15.9 | 108.8% | |
Return on capital | % | 31.0 | 24.9 | 124.6% | |
Exports to sales | % | 4.0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | 273 | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 273 | 872 | 31.3% | |
Fx outflow | Rs m | 2 | 4,466 | 0.0% | |
Net fx | Rs m | 271 | -3,594 | -7.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -313 | 1,235 | -25.3% | |
From Investments | Rs m | -489 | -569 | 85.8% | |
From Financial Activity | Rs m | 769 | -682 | -112.6% | |
Net Cashflow | Rs m | -33 | -12 | 262.1% |
Indian Promoters | % | 25.5 | 75.0 | 34.0% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 9.2 | 0.0 | - | |
FIIs | % | 0.0 | 1.1 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 65.3 | 23.9 | 273.2% | |
Shareholders | 13,061 | 3,357 | 389.1% | ||
Pledged promoter(s) holding | % | 99.7 | 0.0 | - |
Compare AMAR REMEDIES With: EMAMI LINC PEN & PLASTICS MARICO P&G HYGIENE GODREJ CONSUMER
Compare AMAR REMEDIES With: P&G (US) UNILEVER PLC. (UK) HYPERMARCAS (Brazil)
Indian share markets witnessed heavy selling pressure today despite the US administration saying it would bring a stimulus package even without the opposition's support.
For the quarter ended September 2020, RELAXO FOOTWEARS has posted a net profit of Rs 751 m (up 6.5% YoY). Sales on the other hand came in at Rs 6 bn (down 7.4% YoY). Read on for a complete analysis of RELAXO FOOTWEARS's quarterly results.
For the quarter ended June 2020, RELAXO FOOTWEARS has posted a net profit of Rs 242 m (down 51.3% YoY). Sales on the other hand came in at Rs 4 bn (down 43.9% YoY). Read on for a complete analysis of RELAXO FOOTWEARS's quarterly results.
For the quarter ended March 2020, RELAXO FOOTWEARS has posted a net profit of Rs 518 m (down 4.8% YoY). Sales on the other hand came in at Rs 5 bn (down 15.0% YoY). Read on for a complete analysis of RELAXO FOOTWEARS's quarterly results.
For the quarter ended December 2019, RELAXO FOOTWEARS has posted a net profit of Rs 542 m (up 52.0% YoY). Sales on the other hand came in at Rs 6 bn (up 8.8% YoY). Read on for a complete analysis of RELAXO FOOTWEARS's quarterly results.
Here's an analysis of the annual report of RELAXO FOOTWEARS for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of RELAXO FOOTWEARS. Also includes updates on the valuation of RELAXO FOOTWEARS.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More